Skip to content

Author

Martino Pedrani

We have 4 of 29 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Prognostic Value of Baseline High-Uptake PSMA Tumor Volume Fraction in Metastatic Castration-Resistant Prostate Cancer Patients Treated with [177Lu]Lu-PSMA Radioligand Therapy

Simple Summary Lutetium-177 prostate-specific membrane antigen radioligand therapy is an effective option for metastatic castration-resistant prostate cancer, yet a substantial proportion of patients progress early and no validated PSMA-PET/CT biomarker is available to identify them before treatment. In 63 patients, we...

M. Cuzzocrea, Giovanna Pecoraro, C. Iacovitti et al. · 0 citations
Review Open access Oct 2026

Global disparities in the availability and reimbursement of systemic therapies for renal cell carcinoma: results of the International ARON-AID Survey

Abstract Background Renal Cell Carcinoma (RCC) represents a growing global health burden, with rising incidence and mortality worldwide. Despite major therapeutic advances, access to novel systemic treatments remains uneven across countries and regions. Methods We conducted a cross-sectional, web-based international su...

Y. Ürün, K. Sridharan, A. Zgura et al. · 0 citations
Review Open access Sep 2026

Intratumoral Human Papillomavirus in Advanced Prostate Cancer: Systematic Review, Meta-Analysis, and Real-World Evidence from the Largest Cohort to Date

The etiopathogenesis of prostate cancer (PCa) is complex and involves multiple hormonal and environmental factors. Among these, the role of infectious agents remains controversial. Human papillomavirus (HPV) is known to promote carcinogenesis in epithelial tumors and has also been detected, albeit inconsistently, in PC...

D. Brenna, Marialuisa Puglisi, Samantha Epistolio et al. · 0 citations
Review Open access Jul 2026

DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives

Delta-like ligand 3-directed therapies may reshape the management of DLL3-expressing prostate cancer if ongoing efforts to refine biomarkers improve patient enrichment and optimize trial design are successfully translated into clinical practice.

Giovanna Pecoraro, A. De Giorgi, G. Montelatici et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.